0001770141-24-000036.txt : 20240401 0001770141-24-000036.hdr.sgml : 20240401 20240401082750 ACCESSION NUMBER: 0001770141-24-000036 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240401 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UpHealth, Inc. CENTRAL INDEX KEY: 0001770141 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 833838045 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38924 FILM NUMBER: 24805710 BUSINESS ADDRESS: STREET 1: 14000 S. MILITARY TRAIL STREET 2: SUITE 203 CITY: DELRAY BEACH STATE: FL ZIP: 33484 BUSINESS PHONE: 888.424.3646 MAIL ADDRESS: STREET 1: 14000 S. MILITARY TRAIL STREET 2: SUITE 203 CITY: DELRAY BEACH STATE: FL ZIP: 33484 FORMER COMPANY: FORMER CONFORMED NAME: GigCapital2, Inc. DATE OF NAME CHANGE: 20190308 8-K 1 uph-20240401.htm 8-K uph-20240401
0001770141false00017701412024-03-182024-03-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

April 1, 2024
Date of Report (date of earliest event reported)

UpHealth, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
 of incorporation or organization)
001-38924
(Commission
 File Number)
83-3838045
(I.R.S. Employer
 Identification Number)
14000 S. Military Trail, Suite 203
Delray Beach, FL 33484
(Address of principal executive offices, including zip code)
(888) 424-3646
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
 Symbols
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
UPH(1)
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  





___________________________________________________
(1)On December 11, 2023, UpHealth, Inc. (the “Company”) received written notice from the staff of NYSE Regulation that it has commenced proceedings to delist the common stock, par value $0.0001 per share, of the Company (ticker symbol: UPH) (the “Common Stock”), from the New York Stock Exchange (“NYSE”), and suspended trading in the Common Stock pending the completion of such proceedings. As a result, effective December 12, 2023, the Common Stock is trading in the over-the-counter market under the symbol “UPHL”. The Company timely filed an appeal of this determination with the NYSE and requested a hearing before the NYSE Regulatory Oversight Committee’s Committee for Review. On January 12, 2024, the NYSE granted the Company’s request for a hearing, which was originally scheduled to occur on April 17, 2024 but is currently being rescheduled to a later date.





Item 8.01Other Events.

On April 1, 2024, the Company issued a press release, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.




Item 9.01
Financial Statements and Exhibits.

(d) Exhibits
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
.

















































SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 1, 2024                         UPHEALTH, INC.

By:
/s/ Martin S.A. Beck
Name:
Martin S. A. Beck
Title:
Chief Executive Officer

EX-99.1 2 exhibit991-glocalpressrele.htm EX-99.1 Document
Exhibit 99.1
UpHealth Holdings Takes Steps to Enforce the International Court of Arbitration’s Final Award to UpHealth Holdings of more than $110 Million in Damages in Breach of Contract Lawsuit Involving the 2020 Purchase by UpHealth of Glocal Healthcare Systems

DELRAY BEACH, Fla., April 1, 2024 (GLOBE NEWSWIRE) – UpHealth, Inc. (“UpHealth”) (OTC: UPHL), a leading provider of a full continuum of behavioral health solutions through the utilization of evidence-based treatments and services, today provided an update on the efforts of UpHealth Holdings, Inc. (“Holdings”), a wholly-owned direct subsidiary of UpHealth, to enforce the International Court of Arbitration of the International Chamber of Commerce (the “ICA”)’s Final Award to Holdings and against Glocal Healthcare Systems (“Glocal”) and several of Glocal’s officers and shareholders (together with Glocal, the “Respondents”).

Holdings, pursuant to a Share Purchase Agreement dated October 30, 2020, acquired a supermajority of the shares of Glocal in a series of transactions from November 20, 2020 to August 27, 2021 and, as the Tribunal noted, “it is incontrovertible that [Holdings] holds 94.81% of the shares in Glocal”. In particular, the Tribunal found that the Respondents “failed to give [Holdings] control of [Glocal]” after the closing of the acquisition, despite the payment in full of the acquisition consideration, and noted that the Calcutta High Court also agreed that Holdings has invested approximately Rs 2100 crores in Glocal.

Holdings acquired Glocal in order to provide it with the capital and advanced technology required to increase the number of comprehensive primary care and specialty consultations provided to vulnerable populations in India’s rural and dense urban centers through Glocal’s hospitals and onsite digital dispensaries and clinics. In addition to investing millions of U.S. dollars in working capital to fund Glocal’s growth, UpHealth also commissioned a strategic study by McKinsey & Co. and hired local Indian executives with extensive multinational experience to enable even more patients across India to receive high quality, affordable healthcare services.

In the Final Award transmitted on March 18, 2024, the arbitral tribunal (“Tribunal”) found the Respondents liable for breach of contract and directed them to pay Holdings up to $110.2 million in damages, as well as most of the legal costs and other expenses that Holdings incurred in the arbitration. The $110.2 million damages are apportioned based on the shareholders percentage of each of the Indian directors and shareholders of Glocal: 34.38% to be paid by Dr. Syed Sabahat Azim, 34.38% by Richa Sana Azim, 4.69% by Mr. Gautam Chowdhury, 22.54% by Mr. Meleveetil Damodaran, and 4.02% by Kimberlite Social India Private Limited.

Holdings is in the process of filing an ‘Enforcement Petition’ to immediately enforce certain portions of the Final Award and has filed a petition, which is expected to be heard on April 2, 2024, under Section 9 of the (Indian) Arbitration and Conciliation Act, 1996 seeking certain interim reliefs in aid of the Final Award including requiring Respondents to disclose and to not alienate their assets and requiring each Respondent to fund capital in amounts equal to their apportionment of the Final Award.

“UpHealth Holdings acquired Glocal in 2021 to embark in a purposeful mission to provide high-quality medical care to the underserved communities in India’s rural and dense urban centers through Glocal’s hospitals and onsite digital dispensaries and clinics and we continue to believe in this mission. As the ICA confirmed and validated UpHealth’s ownership of Glocal as per the lawfully executed purchase agreement, it is critically important to pursue enforcement of the Tribunal’s Final Award to recover and take control of our assets. This will provide further confidence with other foreign investors to continue to invest in India in order to better the access of vulnerable populations to high quality, cost-effective healthcare services,” said Martin Beck, Chief Executive Officer of UpHealth.

About UpHealth

UpHealth, Inc. is a leading provider of a full continuum of behavioral health solutions through the utilization of evidence-based treatments and services. Operating through its TTC Healthcare, Inc. subsidiary, UpHealth targets mental health issues and substance use disorders with services provided by psychiatrists, physicians, neurologists, licensed therapists, and clinical social workers. The company’s levels of care include detox, residential, partial hospitalization programs, intensive outpatient programs, outpatient, and telehealth. UpHealth’s clients include health plans, healthcare providers and community-based organizations. For more information, please visit https://uphealthinc.com.



Forward-Looking Statements

This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Such forward-looking statements include, but are not limited to, statements regarding the enforcement of the Final Award and the amounts to be paid to Holdings by the Respondents pursuant to the Final Award, control of Glocal and its operation, the projected operation and financial performance of UpHealth and its various subsidiaries, its product offerings and developments and reception of its product by customers, and UpHealth’s expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future revenue and the business plans of UpHealth’s management team. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of UpHealth considering their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on UpHealth as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting UpHealth will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including whether the Respondents will comply with the Final Award, including by paying the amounts awarded to Holdings as set forth therein, uncertainty with respect to how the Indian courts shall decide various matters that are before them, whether UpHealth will be able to regain and sustain compliance with the continued listing standards of the NYSE or comply with the initial listing standards of another national securities exchange, the ability of UpHealth to service or otherwise pay its debt obligations, including to holders of UpHealth’s convertible notes, the mix of services utilized by UpHealth’s customers and such customers’ needs for these services, market acceptance of new service offerings, the ability of UpHealth to expand what it does for existing customers as well as to add new customers and that UpHealth will have sufficient capital to operate as anticipated. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. UpHealth undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as may be required under applicable securities laws.

EX-101.SCH 3 uph-20240401.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 uph-20240401_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 uph-20240401_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 18, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 01, 2024
Entity Registrant Name UpHealth, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38924
Entity Tax Identification Number 83-3838045
Entity Address, Address Line One 14000 S. Military Trail
Entity Address, Address Line Two Suite 203
Entity Address, City or Town Delray Beach
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33484
City Area Code 888
Local Phone Number 424-3646
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol UPH(1)
Security Exchange Name NYSE
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001770141
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://uphealthinc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports uph-20240401.htm uph-20240401.xsd uph-20240401_lab.xml uph-20240401_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "uph-20240401.htm": { "nsprefix": "uph", "nsuri": "http://uphealthinc.com/20240401", "dts": { "inline": { "local": [ "uph-20240401.htm" ] }, "schema": { "local": [ "uph-20240401.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "uph-20240401_lab.xml" ] }, "presentationLink": { "local": [ "uph-20240401_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://uphealthinc.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "uph-20240401.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "uph-20240401.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://uphealthinc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001770141-24-000036-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001770141-24-000036-xbrl.zip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uph-20240401_htm.xml IDEA: XBRL DOCUMENT 0001770141 2024-03-18 2024-03-18 0001770141 false 8-K 2024-04-01 UpHealth, Inc. DE 001-38924 83-3838045 14000 S. Military Trail Suite 203 Delray Beach FL 33484 888 424-3646 false false false false Common Stock, par value $0.0001 per share UPH(1) NYSE true false